-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Ducp/I0KKICbhES9jcnHphP5fBCAIXlgJl7jUNF8sGWrwyoZSTcIWHcDgZ4JlIxH JiyzqxBd80FRtc7lwp5MKQ== 0000950129-02-003029.txt : 20020612 0000950129-02-003029.hdr.sgml : 20020612 20020612161618 ACCESSION NUMBER: 0000950129-02-003029 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20020612 FILED AS OF DATE: 20020612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CENTERPULSE LTD CENTRAL INDEX KEY: 0001041073 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14654 FILM NUMBER: 02677451 BUSINESS ADDRESS: STREET 1: ZURCHERSTERSTRASSE 12 CITY: 8401 WINTERTHUR SWIT STATE: V8 BUSINESS PHONE: 7135616300 MAIL ADDRESS: STREET 1: SULTZER MEDICAL LTD STREET 2: ZURCHERSTRASSE 12 CITY: WINTERTHUR, SWITZERL FORMER COMPANY: FORMER CONFORMED NAME: SULZER ORTHOPEDICS LTD DATE OF NAME CHANGE: 19970616 FORMER COMPANY: FORMER CONFORMED NAME: SULZER MEDICA LTD DATE OF NAME CHANGE: 19970709 6-K 1 h97675e6vk.txt CENTERPULSE LTD. - DATED 6/12/2002 FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 June 12, 2002 Centerpulse Ltd. ---------------- (Translation of Registrant's Name Into English) Andreasstrasse 15 8050 Zurich Switzerland ----------- (Address of Principal Executive Offices) (Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.) Form 20-F X Form 40-F ------- ------ (Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.) Yes No X ------ ------- (If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- ) ------------------ Centerpulse Ltd. is filing this Report on Form 6-K regarding the plan to sell its cardiac and vascular divisions and to furnish the press release which was made public on June 12, 2002, and is attached as Exhibit 99.1 to this Report on Form 6-K. Exhibit 99.1 News Release - Centerpulse to concentrate on core business aspects and plans to sell Cardiac and Vascular Divisions SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned, thereunto duly authorized. CENTERPULSE LTD. Date: June 12, 2002 /s/ David S. Wise ----------------------------- David S. Wise Authorized Representative EXHIBIT INDEX Exhibit 99.1 News Release - Centerpulse to concentrate on core business aspects and plans to sell Cardiac and Vascular Divisions EX-99.1 3 h97675exv99w1.txt PRESS RELEASE DATED 6/12/2002 [CENTERPULSE LOGO] Centerpulse Ltd. Andreasstrasse 15 CH-8050 Zurich Phone +41 (0) 306 96 96 Fax +41 (0) 306 96 97 www.centerpulse.com Date Media Release Page June 12, 2002 NEWS NEWS NEWS NEWS CENTERPULSE TO CONCENTRATE ON CORE BUSINESS ASPECTS AND PLANS TO SELL CARDIAC AND VASCULAR DIVISIONS ZURICH, JUNE 12, 2002 - THE BOARD OF DIRECTORS OF CENTERPULSE, THE FORMER SULZER MEDICA, HAS DECIDED THAT THE COMPANY WILL FOCUS ON ITS CORE ACTIVITIES OF ORTHOPEDIC, SPINE AND DENTAL IMPLANTS AND BIOLOGICS. THE COMPANY THEREFORE PLANS TO DIVEST ITSELF OF ITS CARDIAC AND VASCULAR DIVISIONS AND HAS CONTRACTED THE LEHMAN BROTHERS INVESTMENT BANK TO ASSIST IN THIS ENDEAVOR. The two Centerpulse Divisions to be sold include the business segments of mechanical and tissue heart valves and products for the treatment of vascular obstructions and diseases. The development of both these divisions has been very positive in the past. The Board of Directors nonetheless decided on this step to give greater focus to Centerpulse's business activities. The Executive Committee is confident that the 960 staff of the two Divisions will continue to perform at an outstanding level during the sale process. Once the process is complete, the company will focus on its core businesses of hip and knee implants (Orthopedics Division), spine implants and instrumentation (Spine-Tech Division), dental implants (Dental Division) and biologics (Biologics Division). Centerpulse will not comment on any potential timing or any other aspects of the process until a transaction is announced. THE SAFE HARBOR STATEMENTS UNDER THE U.S. PRIVATE SECURITIES LITIGATION REFORM ACT 1995 This report contains forward-looking statements including, but not limited to, projections of future performance of materials and products, financial conditions, results of operations and cash flows, containing risks and uncertainties. These statements are subject to change based on known risks detailed from time to time in the Company's Securities and Exchange Commission filings and other known and unknown risks and various other factors which could cause the actual results or performance to differ materially from the statement made herein. MEDIA INQUIRIES: Centerpulse Corporate Communications Beatrice Tschanz Mobile + 41 (0)79 407 08 78 Phone +41 (0)1 306 96 46 Fax +41 (0)1 306 96 51 E-mail: press-relations@centerpulse.com.Date INVESTOR RELATIONS: Anja Stubenrauch Phone +41(0)1 306 98 25 Fax +41(0)1 306 98 31 E-mail: investor-relations@centerpulse.com (Swiss Stock Market symbol: CEPN, New York Stock Exchange symbol: CEP) THIS NEWS RELEASE IS AVAILABLE ON THE INTERNET AT: www.centerpulse.com (sulzermedica.com). THE COMPANY`S QUARTERLY REPORT IS AVAILABLE UNDER: www.centerpulse.com (www.sulzermedica.com) "Investors/Financial reports" -----END PRIVACY-ENHANCED MESSAGE-----